SS- 1 Use of Clozaril ® and Zyprexa ® as Concomitant Medication (Simultaneous Use)  69 Clozaril patients used Olanzapine as concomitant medication  17 Zyprexa patients used Clozapine as concomitant medication  WLW analysis results after excluding above patients (P =.021) ClozarilZyprexa N = 421N = 473 Type Type

SS- 2 Suicide History at Baseline Patients, n (%) Clozaril ® Zyprexa ® N = 490N = 490 Suicide history Lifetime attempts, n (15.7)86(17.6) 1124(25.3)99(20.2) (31.4)157(32.0) (12.2)75(15.3) > 575(15.3)72(14.7) Missing0(0.0)1(0.2) Mean3.6(7.5)3.2(4.5) Median 2 2 Range Suicide history Lifetime attempts, n (15.7)86(17.6) 1124(25.3)99(20.2) (31.4)157(32.0) (12.2)75(15.3) > 575(15.3)72(14.7) Missing0(0.0)1(0.2) Mean3.6(7.5)3.2(4.5) Median 2 2 Range CSR ABA 451-Clozaril §Treatment resistance determined by clinical assessment. 8

SS- 3 Number and Percent of Type 1 or Type 2 Events by Diagnosis Subgroup Clozaril ® Zyprexa ® Eventsn/N%K-M § (%)n/N%K-M § (%) Schizophrenia Type 151/ / Type 267/ / Schizoaffective Type 151/ / Type 253/ / §Kaplan-Meier estimates of cumulative probability of event at Week 104.

SS- 4 Retrieved Dropout Patients With Type 1 Events Events, (%) Clozaril ® N = 61 Zyprexa ® N = 60 No Type 1 event41 (67.2)35 (58.3) Type 1 event20 (32.8)25 (41.7) Clozaril and 3 Zyprexa patients had Type 1 events after discontinuation.

SS- 5 WLW and Cox’s Analyses of Type 1 and Type 2 Events Excluding Followup Data After Discontinuations Hazard ratio95% CIP value WLW.006 Cox’s proportional hazard analysis Type , Type ,

SS- 6 Influence of Change in Blinded Psychiatrist Number (%) of Patients With Worsening in CGI-SS-BP of Type 2 Event Clozaril ® Zyprexa ® Worsening CGI-SS-BP, score 6 or 7 (with a change in BP) 138 Change in a BP occurred after Type 2 event 75 Change in BP before Type 2 event63 19

SS- 7 Agreement Between SMB and Blinded Psychiatrist With Regard to Occurrence of Type 1 Events  Concordance 90.5% (84% all)  2 possible explanations for discrepancies – BP evaluation of Type 1 event was not subject to challenge. All SMB determinations required consensus of all 3 SMB members – SMB reviewed all PEP (n = 577) whereas BP assessed on average PEPs (range (0 - 42); less variability in reviewing PEP by SMB could be expected  Primary endpoint, patient’s first SMB-determined Type 1 event, prospectively defined and agreed upon with FDA  High degree of agreement between SMB and BPs regarding this endpoint confirms validity of endpoint for demonstrating efficacy in patients at risk for suicidal behavior 19

SS- 8 Cox’s Analyses of Patients With Type 1 Events as Determined by SMB and BP 19 Hazard ratio95% CIP value SMB , BP , Both SMB and BP agreed ,

SS- 9 Number of Patients with Score of 6 or 7 on CGI-SS-BP (Type 2 Event) Clozaril ® 38 Zyprexa ® 42 CGI-SS-BP not assessed after discontinuation

SS- 10 ClozarilZyprexa SchizoaffectiveN = 190N = 181 Baseline mean Mean change from baseline P value<.001 SchizophreniaN = 300N = 309 Baseline mean Mean change from baseline P value<.001